pharmatimes : declared in US nod for Novartis’ breast cancer drug Kisqali

Novartis' selective cyclin-dependent kinase inhibitor Kisqali has been approved by the US Food and addiction Administration as a treatment for patients with a certain form of breast cancer. Despite available therapies, around 40,000 people are dying every year in the US from advanced breast cancer. It's a moment to celebrate when such ground-breaking scientific work results in a new treatment option for women with advanced breast cancer." "We're committed to the fight against cancer and so we are absolutely delighted that Novartis has received this first approval of a cancer drug arising from our productive collaboration," Harren Jhoti, President and CEO of Astex, UK, said. More than half of patients taking Kisqali plus letrozole remained alive and progression free at the time of interim analysis, therefore median progression free survival could not be determined.

FDA approves Novartis drug as first-line treatment for breast cancer

CLOSE X Edit Favorites Enter up to 25 symbols separated by commas or spaces in the text box below. This will now be your default target page; unless you change your configuration again, or you delete your cookies. Are you sure you want to change your settings? These symbols will be available during your session for use on applicable pages. If, at any time, you are interested in reverting to our default settings, please select Default Setting above.If you have any questions or encounter any issues in changing your default settings, please email isfeedback@nasdaq.com CLOSE X Please confirm your selection: You have selected to change your default setting for the Quote Search.


Kisqali (KISS'-kahl-lee) is taken along with an older Cancer drug called letrozole that works differently. U.S. regulators have approved a new drug as an initial treatment for postmenopausal women with a type of advanced breast cancer. About 40 percent of U.S. women diagnosed with breast cancer have this type, according to the American Cancer Society. The drug, called Kisqali and developed by Swiss drugmaker Novartis AG, is a pill that works to slow the spread of cancer by blocking two proteins that can stimulate growth and division of cancer cells. Kisqali, part of the drug class called kinase inhibitors, is taken daily for three weeks, followed by a one-week break.



collected by :Lucy William

To follow all the new news about Disease !!! All you need to know about all kinds of diseases